dr. costa on biomarkers beyond pd-l1 for immunotherapy in nsclc
Published 7 years ago • 268 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
1:29
dr. devarakonda on biomarkers beyond pd-l1 in nsclc
-
1:24
dr. lilenbaum on pd-l1 as a predictive biomarker for immunotherapy in lung cancer
-
1:34
evolving role of pd-l1 as a biomarker
-
1:03
dr. barbara j. gitlitz on why pd-l1 is not a good biomarker for immunotherapy in lung cancer
-
1:15
dr. brahmer on immunotherapy beyond pd-1/l1 in nsclc
-
1:21
dr. kim discusses pd-l1 as a biomarker in lung cancer
-
1:41
dr. goldberg on pd-l1 as a biomarker in lung cancer
-
1:30
dr. sabari discusses immunotherapy biomarkers in nsclc
-
1:14
dr. levy on investigational biomarkers of response to immunotherapy in nsclc
-
4:50
nsclc: challenges with pd-l1 as biomarker
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3i pd-l1 overexpression
-
0:46
immune checkpoint inhibitors: recent progress and potential biomarkers - 3iv pd-l1 overexpression
-
1:18
dr. joel neal on impact of pd-l1 tests on pembrolizumab, nivolumab efficacy in frontline nsclc
-
7:13
nsclc: immunotherapy beyond progression
-
1:16
dr. levy on positive and negative biomarkers for immunotherapy in lung cancer
-
1:00
dr. nadler discusses role of pd-l1 in squamous nsclc
-
4:47
pd-l1 biomarker testing
-
9:54
is the pd-l1 biomarker ready for prime time?
-
1:04
sonja althammer on role of cd8 and pd-l1 biomarkers for immunotherapy in nsclc